{
  "docId": "019de073-9947-75c9-ab6d-01a31b39af7e",
  "docSlug": "f6e6ee19ba9d775ca06fb17f83eb8b7f",
  "documentTitle": "Third Harmonic Bio | IPO Presentation Deck | 24 slides",
  "authorId": "third-harmonic-bio",
  "authorName": "Third Harmonic Bio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 15,
  "pageCount": 24,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "traction",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "The chart shows a pharmacokinetic (PK) profile comparing two formulations of THB001.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de073-9947-75c9-ab6d-01a31b39af7e/15",
  "deckHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e",
  "deckJsonHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e.json",
  "deckAnchorHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.48,
        "x": 0.04,
        "y": 0.235
      },
      "kind": "chart",
      "text": "THB001 Interim Human BioA Data (200mg crossover)",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3881e80d-ce59-4514-b2fe-77256a602e6d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.57,
        "y": 0.33
      },
      "kind": "list",
      "text": "~3x increase in exposure\nFavorable PK profile\nSupports potential for QD dosing\nManufacturing underway to introduce into upcoming clinical studies – no additional tox/clinical requirements to support transition to new formulation",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0b9cdb14-40d4-444f-bfa1-0bbb8bfea0b2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.05,
        "x": 0.46,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "Mean ± SD",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "54b239c5-9127-4314-bf1a-f6ebcf3c87df",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "THB001 CMC Development: Second-Generation Formulation to Enter 2023",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6fc7969a-ce1b-4e85-8d6d-f9e8a43cabfb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "c499b99d-efdb-4242-acac-d1711df4afd6",
      "evidence": "The line chart for THB001 Interim Human BioA Data (200mg crossover) effectively displays data to support the ~3x increase in exposure claim.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 21,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "1637e937-fd9b-4682-939c-d684884ac925",
      "evidence": "The deck presents the limitations of current treatments and the potential benefits of THB001.",
      "position": 0,
      "objective": "What is the cost of not treating mast cell-mediated diseases effectively?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}